Chemoprevention with aerosolized let-7 microrna in mouse models of non-small cell lung cancer (adenocarcinoma andsquamous cell carcinoma)
Ended Awarded Last action
- Contract number
- 75N91019F00130
- Awardee
-
University Of Oklahoma UEI GY8NMUZQXVS7 Part of University Of Oklahoma
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $849,440
Award facts
- Opportunity
-
- PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarker Endpoints, Preclinical Services for Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing Pre-Solicitation · N01CN7701918 · Posted Apr 19, 2018
- PREVENT Cancer Preclinical Drug Development Program Award Notice · Posted May 7, 2018
- Contract value 100% obligated
- $849,440.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Oklahoma City, OK 73126, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $849,440 |
About this award
The National Cancer Institute, a component of the Department of Health and Human Services' National Institutes of Health, awarded an $849,440 firm fixed price contract to the University of Oklahoma Health Sciences Center under the Prevent Preclinical Drug Development Program. The University will deliver on the stated objective of chemoprevention with aerosolized let-7 microRNA in mouse models of non-small cell lung cancer adenocarcinoma and squamous cell carcinoma. Two subcontracts were issued to support pharmacokinetic, pharmacodynamic, and efficacy studies - one to Houston Methodist Hospital for $250,000 and another to the Medical College of Wisconsin for $350,000. The work will be performed in Oklahoma City over a three year period ending August 2022 to advance the development of let-7b miRNA mimetic therapy for lung cancer prevention through preclinical testing.
Quick answers
Who was awarded contract 75N91019F00130?
75N91019F00130 was awarded to University Of Oklahoma by National Cancer Institute (National Institutes of Health) on August 28, 2019.
How much is contract 75N91019F00130 worth?
The government has obligated $849,440 on 75N91019F00130.
Is contract 75N91019F00130 an order under another contract?
Yes. 75N91019F00130 is a delivery order under 75N91019D00020, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91019F00130 competed?
The extent of competition for 75N91019F00130 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award